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Objectives: Hyaluronic acid and corticosteroids are common intra-articular (IA) therapies widely used for
the management of mild to moderate knee osteoarthritis (OA). Many trials evaluating the efﬁcacy of IA
administered therapies commonly use IA saline injections as a placebo comparator arm. Using a
systematic review and meta-analysis, our objective was to assess the clinical beneﬁt associated with
use of IA saline in trials of IA therapies in the treatment of patients with painful knee OA.
Methods: MEDLINE and Embase databases were searched for articles published up to and including
August 14th, 2014. Two reviewers assessed the eligibility of potential reports and the risk of bias of
included trials. We analyzed short (r3 months) and long-term (6–12 months) pain reduction of the
saline arm of included trials using standardized mean differences (SMDs; estimated assuming a null
effect in a comparator group) that were combined and weighted using a random effects model.
Treatment-related adverse events (AEs) were tabulated and presented using descriptive statistics.
Results: From 40 randomized controlled trials (RCTs) eligible for inclusion only 38 provided sufﬁcient
data to be included in the meta-analysis. Based on data with moderate inconsistency IA saline was found
to signiﬁcantly improve short-term knee pain in 32 studies involving 1705 patients (SMD ¼ 0.68; 95%
CI: 0.78 to 0.57; P o 0.001; I2 ¼ 50%). Long-term knee pain was signiﬁcantly decreased following IA
injection with saline in 19 studies involving 1445 patients (SMD ¼ 0.61; 95% CI: 0.76 to 0.45; P o
0.001) with a substantial degree of inconsistency (I2 ¼ 74%). Overall, 29 of the included trials reported on
adverse events, none of which found any serious treatment-related AEs following IA injection with
saline.
Conclusions: Pain relief observed with IA saline should prompt health care providers to consider the
additional effectiveness of current IA treatments that use saline comparators in clinical studies, and
challenges of identifying IA saline injection as a “placebo.”
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Osteoarthritis (OA) is a common condition affecting the adult
population and is characterized by joint pain and dysfunction [1,2].
It is estimated that over 9-million adults in the United States suffer
from symptomatic knee osteoarthritis, with roughly 1 in 3 adults
over the age of 60 having evidence of radiographic knee OA [3,4].
OA also remains a leading contributor to global disability, and as
measured in 2010, both hip and knee OA collectively account for
over 17 million years lived with disability [5].
Non-surgical treatments are integral to the management of
patients suffering from knee OA [6]. To that end, many trials have
evaluated the efﬁcacy of intra-articular (IA) treatments. There has
been controversy on the value of IA treatments since it was
introduced by Waugh in 1938 [7] and popularized by the use of
hydrocortisone by Hollander et al. in 1951 [8]. Indeed, in one of the
ﬁrst clinical trials, IA lactic acid þ Novocain, Novocain alone,
hydrocortisone, saline, and needle stick alone were all equally
effective 6 months after treatment [9]. Despite the controversies
over their beneﬁt, the need for non-surgical therapy for OA exists
and current therapies have included hyaluronic acid [viscosupple-
mentation (HA), crystalline forms of corticosteroids [10,11] and
more recently, platelet-rich plasma (PRP) [12]]. Although such
trials commonly use IA saline injections as a placebo comparator
arm, there has been growing recognition that the administration
of IA saline may not be without effect [2,13]. The potential
therapeutic effect of single puncture and saline injection was ﬁrst
proposed in 1952 by Desmarais [14]. In a systematic review of 198
trials, it was concluded that pain, stiffness, and functional deﬁcits
associated with knee OA, could be effectively managed by placebo
therapy using IA saline, as a large effect size was reported
following this treatment [13]. It must be noted, however, this
conclusion was drawn from a clinically heterogeneous sample,
with a broad range of placebo therapies compared to various active
treatments.
Given the central role of saline injections as a common placebo
intervention in studies of IA treatment for knee OA, a study to
determine the empirical evidence for a potential therapeutic effect
of saline remains warranted, as designating saline as placebo
treatment may be undermining the true effectiveness of current
IA treatments. The objective of this study was to perform a
systematic review and meta-analysis to assess the effect of IA
saline on reducing pain associated with knee OA across random-
ized trials using saline as a control arm against three different IA
therapies—corticosteroid, HA, and PRP.360 duplicates excluded
Title and abstract screened: 1230
1105 arcles excluded
Full-texts screened: 125
87 arcles excluded:
3 Not RCT
18 Not relevant comparator
22 No saline control
1 Populaon
11 Review, comment, conference abstract
11 No relevant outcome
10 Non-English language 
2 Duplicate publicaon
10 Unavailable
40 studies included in 
qualitave synthesis
38 studies included in 
quantave synthesis 
Manual search of references: 2
addional full-texts included
Fig. 1. Study ﬂow diagram.Methods
This study was conducted according to the Cochrane Handbook
for Systematic Reviews of Interventions [11]. Study selection,
assessment of eligibility criteria, data extraction, and statistical
analysis were performed, based on a predeﬁned protocol (PROS-
PERO 2015: CRD42015014487). The ﬁndings are reported in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [15].
Literature search
MEDLINE and Embase databases were systematically searched
for articles published up to and including August 14th, 2014. MeSH
and EMTREE headings were used in various combinations and
supplemented with free text. A search strategy was initially
conducted to capture studies using IA-HA, and a second search
strategy was used to capture studies of corticosteroid or PRP
injection (Appendix 1). An RCT ﬁlter developed by the HealthInformation Research Unit (HiRU) at McMaster University was
applied to the search [16]. No language or publication date
restrictions were applied. Manual review of reference lists of key
articles that fulﬁlled our eligibility criteria, and also use of the
“related articles” feature in PubMed were conducted to identify
additional studies.Study selection
Randomized controlled trials (RCTs) were included if they
compared IA saline to an IA comparator (i.e., corticosteroid, HA,
or PRP) in adults with symptomatic knee OA. No eligibility criteria
were made regarding publication date, presence or absence of co-
interventions, or length of follow-up. Studies selected were limited
to English language. Two reviewers (T.D. and M.B.) independently,
in duplicate, screened titles and abstracts of identiﬁed citations
from the electronic search. Disagreements during abstract screen-
ing were carried forward for full text review. The full texts of
potentially eligible reports were independently evaluated in
duplicate, and disagreements were resolved through a consensus
process to determine ﬁnal eligibility.Data extraction and risk of bias assessment
One reviewer extracted study characteristics from included
studies using a piloted electronic data extraction form. The second
reviewer subsequently spot-checked the data for accuracy against
the trial report. Authors of included studies were contacted if
important data were unclear or not reported. Data were extracted
from graphical representations when required using a graph
digitizing software (GraphClick, Arizona Software, Switzerland).
The primary effectiveness outcome of the study included both
short (r3 months) and long-term (6–12 months) pain reduction.
The time points were extracted from individual trials that were
closest to the pre-speciﬁed follow-up endpoints of this study.
Various scales were used to measure pain across eligible studies
[17]; Thus, if data on more than one scale for pain were provided in
the available article, the previously developed hierarchy by Juhl et
al. [18] was utilized.
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safety outcome for this study and were coded as either “serious” or
“non-serious.” Non-serious AEs resulting from IA injection of saline
included those that are procedure and treatment related—local
superﬁcial infection/ﬂare-ups, hypersensitivity to local anesthesia,
effusions at the injected knee, discomfort at injection site, needle
breakage or separation, and any other local adverse events reported
by the authors of individual trials. A serious adverse event (SAE) was
deﬁned as an “adverse event or suspected adverse reaction that, in
the view of either the investigator or the sponsor, results in any of the
following outcomes: death, a life-threatening adverse event, inpa-
tient hospitalization or prolongation of existing hospitalization, a
persistent or signiﬁcant incapacity or substantial disruption of theTable 1
Characteristics of included studies
Study No. of
patients
Mean age,
years
Female
sex, %
Placebo/control inter
Altman et al. [26] 174 63.3 64 3 mL 0.9% saline
Altman et al. [27] 295 60.8 63 2 mL PBS
Arden et al. [28] 110 60.9 46 3 mL PBS
Baltzer et al. [29] 107 60.3 64 Saline
Chao et al. [30] 39 63.2 12.4 1 mL 0.9% NaCl
Chevalier et al. [31] 129 62.5 68 PBS
Creamer et al. [32] 12 72.2 100 2 mL saline
Cubukcu et al. [33] 10 57.6 100 2 mL saline
Day et al. [34] 124 62 61 Saline
DeCaria et al. [35] 15 72.9 NR 1.2 mL 0.001 mg/mL
Dieppe et al. [36] 12 65 8.1 1 mL saline
Diracoglu et al. [37] 21 56.2 93 0.9% saline
Dixon et al. [38] 33 68.5 54 2 mL 0.2 mg sodium
Dougados et al. [39] 55 69 65 2 mL placebo
Gaffney et al. [40] 42 68 8.6 1 mL 0.9% saline
Henderson et al.b [41] 20 60 75 2 mL buffered saline
Henderson et al.,
1994bb [41]
26 67 69 2 mL buffered saline
Huang et al. [42] 100 64.2 78 2 mL saline
Huskisson et al. [43] 50 64.8 58 2 mL saline
Karlsson et al. [44] 66 71 61 3 mL PBS
Kotevoglu et al. [45] NR 60.1 88.9 2 mL saline
Lohmander et al. [46] 120 58 67 2.5 PBS
Lundsgaard et al. [47] 84 69.6 52.4 2 mL physiological sa
Navarro-Sarabia et al.c
[48]
152 63.9 83.7 2.5 mL saline
Patel et al. [12] 26 53.7 8.17 8 mL normal saline
Petrella et al.d [50] NR 62.6 42.9 2 mL isotonic NaCl so
Petrella et al., 2002bd
[50]
NR 66.3 42.3 2 mL isotonic NaCl so
NSAIDs
Petrella et al. [51] 53 62.4 46.3 2 mL saline
Petrella et al. [49] 50 71 60 Saline
Pham et al. [52] 85 64.9 61.2 2.5 mL saline
Puhl et al. [53] 107 60.8 55 0.25 mg sodium hyal
2.5 mL PBS
Ravaud et al., 1999 [54] 28 63 11 1.5 mL 0.9% NaCl
Raynauld et al. [55] 34 63.3 9 1 mL saline
Scale et al. [56] 40 58.6 50 2 mL buffered saline
Sezgin et al. [57] 19 59.4 68.4 2 mL 0.9% NaCl
Smith et al. [58] 38 66.3 11.8 1 mL saline
Stein et al. [59] 17 66.6 5.2 Saline solution
Strand et al. [60] 128 60.3 60.2 PBS
Tamir et al., 2001 [61] 24 70 71 2 mL PBS
Wobig et al. [62] 60 62 74 2 mL PBS
Wu et al. [63] 54 NR NR 2.5 mL PBS
Yavuz et al. [64] 30 60 6.1 1 mL 0.09% NaCl
Note: Cortico ¼ corticosteroid; HA ¼ hyaluronic acid; NaCl ¼ sodium chloride; NR ¼
a months.
b For the purposes of statistical analysis, the authors stratiﬁed patients into two group
before recruitment; Henderson et al. [41] ¼ Group I (Kellgren and Lawrence (K–L) grad
c Number of patients ¼ number allocated, not the number randomized; mean age
d Same trial; two arms separated arms reported with respect to placebo/control intability to conduct normal life functions, or a congenital anomaly/birth
defect [1] (e.g., post-IA injection septic arthritis).”
For the assessment of methodological quality, both reviewers
independently assessed the risk of bias of included studies using
the Cochrane Risk of Bias tool [19]. The Cochrane Risk of Bias (RoB)
tool separates judgments about risk of bias from inadequate
reporting of methodology. The Cochrane RoB-tool evaluates the
following items: random sequence generation, allocation conceal-
ment, blinding of outcome assessment, incomplete outcome data,
selective reporting, and other biases. Studies were scored as
having high, low, or unclear risk of bias for each component of
the tool. The reviewers resolved discrepancies for each item
through discussion until consensus was reached.vention Comparator No. of
injections
No. of treatment
cycles
Duration of
follow-up, weeks
Short-
term
Long-
term
HA 1 1 13 26
HA 3 1 – 26
HA 1 1 6 –
HA 3 1 13 26
Cortico 1 1 12 –
HA 1 1 12 26
HA 5 1 9 –
HA 3 1 8 –
HA 5 1 18 –
inert HA HA 3 1 3a 6
Cortico 1 1 1 –
HA 3 1 4 –
hyaluronate HA 11 1 15 48
HA 4 1 4 49
Cortico 1 1 6 –
HA 5 1 5 –
HA 5 1 5 –
HA 5 1 – 25
HA 5 1 4 6
HA 3 1 12 26
HA 3 1 – 6
HA 5 1 13 20
line HA 4 1 12 26
HA 5 4 – –
PRP 1 1 3 12
lution HA 3 1 4 –
lution þ HA 3 1 4 –
HA 3 1 6 –
HA 3 1 16 –
HA 3 3 – 12
uronate in HA 5 1 – –
Cortico 1 1 – 24
Cortico 8 1 – 12
HA 2 1 12 –
HA 3 1 3 –
Cortico 1 1 12 24
Cortico 1 1 6 days –
HA 1 1 13 –
HA 5 1 – –
HA 3 1 12 26
HA 5 1 – –
Cortico 1 1 12 –
Not reported; PBS ¼ phosphate buffered saline; PRP ¼ platelet-rich plasma.
s, I and II, on the basis of severity of radiological changes seen on radiographs taken
e I or II); Henderson et al., 1994b ¼ Group II (K–L grade III or IV).
is for the initial whole study sample.
ervention.
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Standardized mean differences (SMDs) were used to summa-
rize results for short- and long-term pain. Only data from the IA
saline arm of the RCTs were used; thereby, calculating a modiﬁed
SMD for each study. As a result, unlike a typical meta-analysis, the
net beneﬁt from being allocated to the “placebo/control group”
could not be estimated. However, it was assumed that a matched
group was available—who did not receive any clinical support—
this was imputed as having an average null-change from baseline.
This assumption of null effect in the group that did not receive any
treatment is conﬁrmed in a previous analysis, that demonstrated a
negligible effect size in knee OA patients who did not receive any
treatment for their condition [13]. Thus, we computed the SMD as
a mean change from baseline and the corresponding standard
deviation (SD) and simulated a “null effect” for contrast with the
same dispersion (i.e., SD) measure as the observed IA saline arm.
The SMDs were combined using the inverse variance method
combining based on a random effects model [20]. When mean
change scores were not presented explicitly, the mean changes
from baseline values were obtained by subtracting the ﬁnal mean
from the baseline mean [19]. When there was not enough
information available to calculate SDs for the change scores or
when SDs were not reported from individual studies, they were
estimated from standard errors, P values, CIs, or ranges where
possible, or they were estimated from similar included studies
[19,21,22].
Heterogeneity was quantiﬁed using the Q-test for heterogene-
ity and inconsistency was interpreted based on I2 index [19,23].
According to the protocol a priori hypotheses were developed to
explain potentially high heterogeneity in the treatment effect
according to the following trial characteristics: presence or
absence of blinding of patients and outcome assessors, one versus
two or more number of treatment cycles, and one or two versus
three versus four or more injections.
Inter-observer agreement was evaluated for reviewer's assess-
ments of study eligibility with the Cohen κ (kappa) coefﬁcient and
inter-observer agreement for the risk of bias assessment with the
weighted κ coefﬁcient [24,25]; all of the coefﬁcients were calcu-
lated using SPSS software (version 21.0; SPSS Inc.). All tests of
signiﬁcance were 2-tailed, and P values of o0.05 were considered
signiﬁcant. Inconsistent and variable reporting of TRAEs and SAEs
did not lend for a pooled analysis, and thus, were tabulated and
presented using descriptive statistics.Fig. 2. Risk of bias assessment of included randomized controlled trials.Results
Included studies and study characteristics
Of 1590 potentially eligible studies identiﬁed, 125 were
reviewed in full. Two additional full text articles were reviewed
following a hand search of reference lists, increasing the
total reviewed articles to 127. Overall, 40 RCTs were included
[12,26–64], of which 31 trials compared IA saline to IA-HA, while
8 trials compared IA saline to IA corticosteroid and only 1 trial
compared IA saline against IA PRP. 38 of the included trials were
entered into the meta-analysis (Fig. 1 and Table 1).
All eligible trials included patients with knee OA as deﬁned by
the American College of Rheumatology criteria, conﬁrmed by the
radiographic Kellgren–Lawrence score, Ahlbäck classiﬁcation,
Larsen score, or other knee OA diagnostic criteria. Of the 13 trials
[26–28,31,41–43,47,48,52,57,60,61] reporting Kellgren–Lawrence
grades of radiographic severity [65]; grade 2 was found in a
median of 39% of participants, and grade 3 in a median of 47.8%
participants. Of the included studies, the mean age of participants63.7 (SD ¼ 4.52), and the mean percentage of women ranged
from 64% (SD ¼ 17%). The longest duration of follow-up
in the trials ranged from 6 days to 52 weeks. Overall, 31 trials
[12,26–29,31–35,38,41–49,51–55,57–62] permitted the use of
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did not allow co-interventions [50,56,63], and in six studies it was
not reported [30,36,37,39,40,64].
All trials were found to have a high (n ¼ 28 [12,26–28,30,
38–54,56,57,59,61–63]) or uncertain (n ¼ 12 [29,31–37,55,58,60,64])
risk of bias (Fig. 2). Inter-observer agreement for the overall risk of
bias assessment was satisfactory (κ ¼ 0.79, 95% CI: 0.65–0.94).
Random sequence generation was adequate in 20 trials, allocation
concealment was ensured in 12 trials, 25 trials were judged to have
adequately blinded participants, and 37 blinded outcome assessors
(Fig. 2). In all, 13 studies [28,31–33,35,36,49,51,52,54,55,58,60] ana-
lyzed all patients according to the intention-to-treat principle.
Pain
As illustrated in Fig. 3, there was a signiﬁcant improvement
in short-term knee pain (r3 months) following IA injection
with saline across 32 studies [12,26,28–41,43,44,46,47,49–51,
56–60,62,64] involving 1705 patients (SMD ¼ 0.68; 95%
CI: 0.78 to 0.57; P o 0.001) with moderate heterogeneity
(I2 ¼ 50%). In addition, there was a signiﬁcant reduction in long-
term knee pain (6–12 months) following IA injection with saline
across 19 studies [12,26,27,29,31,35,38,39,42–47,52,54,55,58,62]
involving 1445 patients (SMD ¼ 0.61, 95% CI: 0.76 to 0.45,
P o 0.001) with substantial amount of heterogeneity (I2 ¼ 74%;
Fig. 4).Fig. 3. Standardized mean differences, shortPooled estimates for both short- and long-term pain varied
when sensitivity analyses were performed according to blinding of
outcome assessors, and number of injections; however, there was
considerable overlap of CIs between strata and P values for
interaction were all negative.
Adverse events
The incidence of serious and non-serious treatment-related AEs
has been summarized in Table 2. Overall, 29 of the included trials
[12,26–29,31,32,34,35,37–39,41–44,47,48,53–56,58–64] reported
on adverse events, none of which found any serious TRAEs
following IA injection with saline.Discussion
Empirical evidence shows that IA saline injections, often used
as a “placebo” or “sham” intervention in clinical trials evaluating IA
interventions for knee OA, provide a statistically signiﬁcant effect
of saline on both short- (r3 months) and long-term (6–12
months) pain relief.
This review has limitations. A major limitation is the poor
methodological quality of a majority of the included trials. SMDs
were used to summarize pooled data, as various measurement
scales were reported between included studies; however, given-term pain (r3 months) from baseline
Fig. 4. Standardized mean differences, long-term pain (6–12 months) from baseline
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appropriate and justiﬁed. Studies entered into the meta-analysis
included a mixture of change from baseline and ﬁnal value scores
for short- and long-term pain. It is inappropriate to combine ﬁnal
value and change scores using SMDs, since the difference in SD
reﬂects no differences in measurement scale, but rather differ-
ences in the reliability of measurements; thus, only change from
baseline values for both outcomes were entered [19]. Where data
were only reported as absolute values, computed change scores as
described previously in the methods for data synthesis were
included. For some studies this required transforming the original
scale (e.g., 5 point WOMAC Likert scale) to a 100-mm visual analog
scale (VAS) to allow for imputation of SDs obtained from other
included studies [66], which may be an extreme assumption given
that their SDs may not be transformable on the same scale;
however, centering our analysis around a single measure would
have limited the number of studies available for a pooled analysis.
Another practical issue with this method of data synthesis is that
baseline and ﬁnal measurements may have been reported for
different numbers of participants due to loss to follow-up. Of the
29 studies entered into the meta-analysis, we were unable to
determine the percentage of patients completing follow-up assess-
ments in seven trials [40,45,50,56,57,62,64], and four trials
[30,46,54,59] reported a loss to follow-up rate of more than 20%,
which may have introduced attrition bias in our estimates. Despite
sensitivity testing with a priori hypotheses, we could not explain
the high heterogeneity seen in the pooled analysis for long-term
pain. We can speculate that this heterogeneity is possibly due to
differences in study methodology and execution, variability in
patient populations, placebo effect, or a combination of these
factors; however this is unclear and not conﬁrmable.
An additional limitation stems from the potential placebo effect
from expected improvement within patients treated with intra-
articular saline for knee OA. Although this may be a contributingfactor to the differences in pain outcomes between no treatment
and IA saline, there is a plausible mechanism and sufﬁcient
evidence to suggest that beneﬁcial effects of IA saline are not
solely due to a placebo effect. We acknowledge that there is a
potential for therapeutic effect to be seen within the group
receiving no treatment, however we can justify our assumption
that this effect would be negligible based on the 0.03, 95% (CI:
0.13 to 0.18) effect size of a “no treatment” group reported
within a previous meta-analysis [13].
Implications for practice and research
Therapeutic interventions without active biologics, including
irrigation or lavage of a joint with sodium chloride, Ringer, or
Ringer and lactate, as well as exploratory arthroscopic procedures
involving thorough rinsing of the joint have shown to be effective
in alleviating pain in osteoarthritic or trauma patients with painful
joints [67–69]. However, the physiological mechanisms contribu-
ting to the antinociceptive effects are poorly understood and there
is no scientiﬁc or biological basis to account for these beneﬁcial
effects. It has been postulated that extensive rinsing through ﬂuid
lavage removes active pain-signaling or pain-mediating molecules
present in the IA joint space, and this technique may also extract
proteoglycans and aggrecans from the superﬁcial cartilage matrix
compartment, thereby transiently promoting the adhesion of
repair cells, which may induce an anti-inﬂammatory response
[70]. Despite controversy between study results of available
literature, overall, joint lavage, whether performed by the closed-
needle-hole technique or through arthroscopic intervention does
appear to be effective for brief periods of time [67,71–73]. IA
injection differs from joint lavage, as the ﬂuid used in IA injection
is not removed from the joint. The aforementioned mediators and
markers removed using lavage thus remain within the joint
following IA injection. Aspiration of the joint prior to IA injection
Table 2
Treatment-related adverse events
Study N randomized N analyzed Serious Non-serious
Number of patients Number of events Number of patients Number of events
Altman et al. [26] 174 174 0 0 15 NR
Altman et al. [27] 295 295 0 0 32 48
Arden et al. [28] 110 110 0 0 6 6
Baltzer et al. [29] 107 107 0 0 30 NR
Chevalier et al. [31] 129 130 0 0 4 NR
Creamer et al. [32] 12 12 NR NR NR 7
Day et al. [34] 124 115 0 0 NR 13
DeCaria et al. [35] 15 15 0 0 0 0
Diracoglu et al. [37] 21 20 0 0 0 0
Dixon et al. [38] 33 NA 0 0 0 0
Dougados et al. [39] 55 48 0 0 0 0
Henderson et al. [41] 46 44 0 0 10 NR
Huang et al. [42] 100 98 0 0 0 0
Huskisson et al. [43] 50 41 0 0 0 0
Karlsson et al. [44] 66 66 0 0 0 0
Lundsgaard et al. [47] 84 80 0 0 0 0
Navarro-Sarabia et al. [48] NA 153 0 0 11 14
Patel et al. [12] 26 23 0 0 0 0
Puhl et al. [53] 107 107 0 0 5 NR
Ravaud et al., 1999 [54] 28 28 0 0 5 0
Raynauld et al. [55] 34 33 0 0 0 0
Scale et al. [56] 40 NA 0 0 0 0
Smith et al. [58] 38 33 0 0 0 0
Stein et al. [59] 17 12 0 0 0 0
Strand et al. [60] 128 128 0 0 33 58
Tamir et al., 2001 [61] 24 20 0 0 11 NR
Wobig et al. [62] 60 NA 0 0 2 NR
Wu et al. [63] 54 51 0 0 0 0
Yavuz et al. [64] 30 30 0 0 0 0
NA, not applicable.
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saline into the joint, hypothetically providing a similar effect to
lavage.
Detailed and thorough reporting of safety information was not
a commonality within the included studies. Safety data should not
be overlooked with respect to HA treatment, and future studies
should ensure that thorough and accurate safety outcomes are
reported.
A recent network meta-analysis assessing the effectiveness of
pharmacologic interventions for knee osteoarthritis demonstrated
that IA therapies were the most effective treatments for knee OA
[74]. When compared with oral placebo, IA placebo was more
effective in alleviating pain [effect size ¼ 0.29 (95% credible
interval: 0.04–0.54)], an observation that a traditional meta-
analysis does not aim to address [74]. This network meta-
analysis also showed that none of the oral NSAIDs were signiﬁ-
cantly superior to IA placebo [74], further strengthening the
support for the potential physiological role of IA saline. This
ﬁnding raises important questions about the extent to which this
therapeutic effect is attributable to a true placebo response versus
physiologic effects after directly injecting a ﬂuid into the knee joint
[74], and about the potential for IA ﬂuids to inﬂuence nociceptive
response and have pathophysiologic beneﬁts [74,75], especially if
any ﬂuid was aspirated from the knee joint [76–78].Conclusions
IA saline injection, though often used as a “placebo” treatment
in clinical trials for knee OA has demonstrated the potential to
provide substantial pain relief in a number of studies. Pain relief
observed with IA saline should prompt health care providers to
consider the additional effectiveness of current IA treatments thatuse saline comparators in clinical studies, and challenges of
identifying IA saline injection as a “placebo.”Appendix 1
Search strategy for MEDLINE (adapted for EMBASE)1 osteoarthritis/
2 osteoarthritis.mp.
3 knee Joint/
4 knee Joint.mp.
5 1 or 2
6 3 or 4
7 5 and 6
8 osteoarthritis, knee/
9 7 or 8
10 exp Injections, Intra-Articular/
11 viscosupplements/
12 viscosupplement$.mp.
13 hyaluronic Acid/
14 hyaluronic Acid.mp.
15 hyaluron$.mp.
16 hylan.mp.
17 healonid.mp.
18 hyalgan.mp.
19 hylectin.mp.
20 hyalﬂex.mp.
21 hylartil.mp.
22 replasyn.mp.
23 suplasyn.mp.
24 polyreumin.mp.
25 nrd 101.mp.
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27 slm 10.mp.
28 neovisc.mp.
29 orthovisc.mp.
30 adant.mp.
31 etapharm.mp.
32 or/10-31
33 9 and 32
34 randomized controlled trial.pt.
35 randomized.mp.
36 placebo.mp.
37 or/34-36
38 33 and 37
39 limit 38 to animals
40 limit 39 to human
41 39 not 40
42 38 not 41Search strategy for MEDLINE (adapted for EMBASE)—Corticosteroid
and PRP1 osteoarthritis/
2 osteoarthritis.mp.
3 knee joint/
4 knee.mp.
5 1 or 2
6 3 or 4
7 5 and 6
8 osteoarthritis, knee/
9 7 or 8
10 corticosteroid$.mp.
11 glucocorticoid$.mp.
12 hydroxycorticosteroid$.mp.
13 exp adrenal cortex hormones/
14 corticoid$.mp.
15 ketosteroid$.mp.
16 androstenedione.mp.
17 methylprednisolone acetate.mp.
18 triamcinolone acetate.mp.
19 betamethasone acetate.mp.
20 triamcinolone hexacetonide.mp.
21 dexamethasone.mp.
22 platelet-rich plasma/
23 platelet-rich plasma.mp.
24 platelet rich plasma.mp.
25 platelet transfusion/
26 platelet transfusion.mp.
27 PRP.mp.
28 blood transfusion, autologous/
29 plasma rich.mp.
30 autologous conditioned plasma.mp.
31 autologous blood.mp.
32 or/10-31
33 9 and 32
34 randomized controlled trial.pt.
35 randomized.mp.
36 placebo.mp.
37 or/34-36
38 33 and 37
39 limit 38 to animals
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